Semaglutide is a prescription-only GLP-1 receptor agonist used in FDA-approved products such as Ozempic, Wegovy, and Rybelsus. Eligibility depends on your health history, goals, BMI, medications, and contraindications. At Chia, we offer clinician-reviewed access to compounded semaglutide injection when clinically appropriate; prescriptions are not guaranteed.
Wondering if semaglutide is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you get a semaglutide prescription online?
Yes, semaglutide can be prescribed after an online medical visit if a licensed clinician decides it is appropriate. The visit should include more than a short checkout form; it should review your goals, medical history, medications, contraindications, and follow-up plan.
Why semaglutide requires a licensed clinician
Semaglutide affects appetite regulation, gastric emptying, insulin secretion, and glucagon secretion through GLP-1 receptors 4. That is why it can help some patients with weight and blood sugar goals, but also why it needs medical screening.
A clinician should check for risks such as pancreatitis history, gallbladder disease, kidney concerns, pregnancy plans, and drug interactions. Semaglutide can also raise hypoglycemia risk when used with insulin or sulfonylureas, so medication review matters 4.
What an online prescription visit should include
- A health questionnaire that asks about weight history, goals, current medications, allergies, and medical conditions.
- Screening for contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, often called MEN2 4.
- A licensed clinician review before any prescription is issued.
- Clear pharmacy information and instructions for use.
- Follow-up support for side effects, dose changes, refill timing, and safety questions.
If you are comparing online care models, our guide to how to get a GLP-1 prescription online explains what safe clinician review should look like.
What is semaglutide and how does it work?
Semaglutide is a glucagon-like peptide-1 receptor agonist, or GLP-1 receptor agonist. It acts on pathways involved in fullness, appetite, blood sugar, and stomach emptying; in one human study, once-weekly semaglutide reduced appetite and energy intake in adults with obesity 5.
Semaglutide, GLP-1 receptors, appetite, fullness, and blood sugar
GLP-1 is a hormone your body already makes. Semaglutide activates the GLP-1 receptor for longer than natural GLP-1, which helps explain effects on satiety, appetite, insulin secretion, glucagon secretion, and gastric emptying 4.
Those effects can also cause side effects. Nausea, vomiting, diarrhea, and constipation are among the most common gastrointestinal adverse effects reported in weight-management studies of semaglutide 2.4 mg 2.
Ozempic, Wegovy, Rybelsus, and compounded semaglutide
Ozempic, Wegovy, and Rybelsus are FDA-approved semaglutide products with different labels, forms, and uses. Ozempic and Rybelsus are used for type 2 diabetes mellitus, while Wegovy is labeled for chronic weight management and certain cardiovascular-risk uses in people with overweight or obesity 4.
Compounded semaglutide via a state-licensed 503A compounding pharmacy is a different regulatory category. It is not FDA-approved, is not reviewed by FDA before marketing, and is not interchangeable in approval status, labeling, device, formulation, or regulatory review with FDA-approved brand-name products 3.
Who may qualify for a semaglutide prescription?
Semaglutide eligibility is individualized. A clinician looks at BMI, weight-related health conditions, treatment goals, medication history, contraindications, and whether the expected benefits outweigh the risks.
Common weight-management eligibility factors
For FDA-approved Wegovy, the weight-management indication includes adults with obesity, often defined as BMI ≥30, or adults with overweight, BMI ≥27, plus at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia 2. BMI is only one part of the review.
Human randomized trials of semaglutide 2.4 mg studied adults with overweight or obesity alongside lifestyle intervention 1. Those trial results help clinicians understand the active ingredient, but they do not guarantee individual results and do not establish outcomes for compounded formulations.
Health history, medication review, and contraindication screening
A medical review should cover personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis, gallbladder disease, pregnancy, kidney problems, and current diabetes medications 4. This is also the time to discuss common gastrointestinal side effects and what follow-up will look like.
Why a prescription is never automatic
A prescription is a clinical decision, not a formality. Sometimes a clinician may recommend a different medication, more lab review, an in-person visit, or no medication if the safety profile does not fit.
3-min quiz
Explore semaglutide access with Chia
Chia offers compounded semaglutide injection with plans currently starting at $249/mo. A licensed US provider reviews your intake and prescribes only when clinically appropriate; a prescription is not guaranteed. Compounded drugs are not FDA-approved.
How do Ozempic, Wegovy, Rybelsus, and compounded semaglutide compare?
Ozempic, Wegovy, Rybelsus, and compounded semaglutide all involve semaglutide, but they are not the same product. They differ by FDA-approved indication, dosage form, labeling, access path, and regulatory review.
| Option | Form | Main FDA-approved use | Access path | Key notes |
|---|---|---|---|---|
| Ozempic | Injection | Type 2 diabetes mellitus; also has cardiovascular-risk labeling in certain patients | Prescription through a licensed clinician and pharmacy | Not offered by Chia |
| Wegovy | Injection | Chronic weight management for eligible adults and adolescents; certain cardiovascular-risk uses | Prescription through a licensed clinician and pharmacy | Not offered by Chia |
| Rybelsus | Tablet | Type 2 diabetes mellitus | Prescription through a licensed clinician and pharmacy | Not offered by Chia |
| Compounded semaglutide injection | Injection | Not FDA-approved | Prescription, when appropriate, and dispensing through a state-licensed 503A compounding pharmacy | Offered by Chia as injection only, with microdosing plans available |
Can you buy Ozempic as a pill?
Ozempic is an injectable semaglutide product. Rybelsus is an oral semaglutide tablet approved for type 2 diabetes mellitus, but Chia does not offer Rybelsus or oral semaglutide 4.
If you are specifically researching injections, our guide to semaglutide injections online explains how prescription review, pharmacy fulfillment, and delivery work.
How much does semaglutide cost, and does insurance cover it?
Semaglutide cost depends on the product, pharmacy, insurance plan, indication, prior authorization rules, and cash-pay program. Brand-name and compounded options are priced differently, and insurance coverage varies widely.
Brand-name semaglutide, insurance, prior authorization, and cash-pay pricing
Insurance plans often use prior authorization for GLP-1 medications. Coverage may depend on diagnosis, BMI, weight-related comorbidities, prior medication trials, and plan rules; cost can also change by deductible, pharmacy benefit, and supply limits.
Wegovy’s cost has been noted as a limiting factor in clinical reviews of semaglutide 2.4 mg for weight management 2. If your plan does not cover a brand-name product, a clinician can still help you compare safe, legal options.
Compounded semaglutide cost factors
Compounded semaglutide pricing can vary by provider model, pharmacy, follow-up support, supplies, and whether the plan includes clinician messaging. At Chia, compounded semaglutide injection plans currently start at $249/mo; see the semaglutide product page for current pricing.
For a deeper safety and cost comparison, see our guide to compounded semaglutide online.
What are the downsides and side effects of semaglutide?
Semaglutide side effects are most often gastrointestinal, but serious risks can occur. Benefits and risks should be discussed together before starting and during follow-up.
Common gastrointestinal side effects
In reviews of semaglutide 2.4 mg for weight management, nausea, vomiting, diarrhea, and constipation were the most common side effects 2. These symptoms are one reason clinicians usually monitor tolerability over time rather than treating semaglutide as a one-time prescription.
Serious risks to discuss with a clinician
Important risks include gallbladder disease, pancreatitis, kidney problems related to dehydration from severe vomiting or diarrhea, and low blood sugar when combined with insulin or sulfonylureas 4. Semaglutide labeling also includes a warning related to medullary thyroid carcinoma risk based on animal data, so clinicians screen for personal or family history of medullary thyroid carcinoma and MEN2 4.
In the SELECT cardiovascular outcomes trial, participants with overweight or obesity and established cardiovascular disease without diabetes received semaglutide 2.4 mg once weekly; semaglutide reduced major adverse cardiovascular events compared with placebo, while gastrointestinal adverse events were also more common 6. Individual results vary.
What happens if treatment is stopped?
Weight regain can happen after stopping semaglutide. In the STEP 1 extension, participants regained weight after semaglutide withdrawal, and cardiometabolic improvements moved back toward baseline 7.
The STEP 4 trial also found that continued semaglutide helped maintain and extend weight loss compared with switching to placebo after an initial treatment period 8. This does not mean everyone must stay on treatment forever, but it does mean long-term planning matters.
Semaglutide at Chia: clinician-reviewed compounded injection access
At Chia, we offer compounded semaglutide injection through a 100% online care model. A licensed US provider reviews your intake and prescribes only when clinically appropriate; a prescription is not guaranteed.
Online questionnaire, licensed US provider review, and eligibility
You start with a short health questionnaire. Our providers review your goals, BMI, health history, medications, and safety factors, then decide whether semaglutide or another path makes sense.
Compounded semaglutide injection from state-licensed 503A pharmacies
When prescribed through Chia, compounded semaglutide is dispensed by US state-licensed 503A compounding pharmacies and shipped to your door. Chia does not offer Ozempic, Wegovy, Rybelsus, or oral semaglutide.
Provider-guided dosing, microdosing plans, portal messaging, and home shipping
Dosing is provider-guided and adjusted over time. Chia’s semaglutide offering includes microdosing plans where clinically appropriate, and patients can message their care team through the patient portal between visits.
When Chia may discuss Weight + Energy with NAD+ and a GLP-1
Some patients ask about energy while using a GLP-1. When clinically appropriate, Chia may discuss the Weight + Energy protocol, which includes NAD+ injection plus a choice of GLP-1; plans currently start at $309/mo.
| Chia option | What it includes | Form | Current starting price | Best fit to discuss with a provider |
|---|---|---|---|---|
| Semaglutide | Compounded semaglutide | Injection | From $249/mo | Patients exploring a GLP-1 prescription for weight-management goals |
| Weight + Energy | NAD+ injection plus choice of GLP-1 | Injection-based protocol | From $309/mo | Patients who want to discuss GLP-1 care with NAD+ protocol context |
How can you spot unsafe semaglutide offers online?
Unsafe semaglutide offers often skip the prescription step or hide who is prescribing and dispensing the medication. A licensed provider and a state-licensed pharmacy are the key safety checkpoints.
No-prescription offers, research chemicals, and fake pharmacies
The FDA warns consumers to watch for companies that do not require screening and a prescription from a licensed clinician, make claims that compounded drugs are the same as FDA-approved drugs, advertise prices that seem too good to be true, or lack clinician support after purchase 3.
Avoid research-chemical sites selling semaglutide for self-use. Semaglutide should be used only under clinician supervision with a valid prescription and pharmacy dispensing.
FDA cautions about compounded GLP-1 drugs
FDA states that unapproved GLP-1 drugs, including compounded semaglutide and tirzepatide, do not undergo FDA review for safety, effectiveness, or quality before marketing 3. FDA also advises patients to obtain a prescription from a clinician and fill it at a state-licensed pharmacy 3.
What should you ask before starting semaglutide?
Before starting semaglutide, ask about goals, risks, follow-up, cost, and alternatives. A good plan should explain what to expect, what side effects to report, and how your clinician will reassess treatment over time.
Questions about goals, risks, follow-up, cost, and alternatives
- What health goals are we treating: weight, blood sugar, cardiovascular risk, or another concern?
- What side effects should I expect, and which symptoms should prompt urgent care?
- Do any of my medications increase hypoglycemia risk?
- How will follow-up work if I have nausea, vomiting, diarrhea, constipation, or dose-tolerance issues?
- What are my total monthly costs, including medication, visits, supplies, and shipping?
- What happens if I stop treatment or need to pause it?
When to use Chia’s quiz or DoctorMCP access path
If you want a clinician-reviewed online evaluation, you can start with Chia’s eligibility quiz. If you use an AI agent that can connect to health services, Chia is also reachable through DoctorMCP at mcp.chia.health as an access path to begin the same type of medical evaluation.
You can also read our broader guide to GLP-1 medications online if you are comparing semaglutide with other GLP-1 options.
3-min quiz
Start your online visit
Chia’s online visit includes a health questionnaire and licensed US provider review. If clinically appropriate, we can prescribe compounded semaglutide injection from state-licensed 503A pharmacies with home delivery. A prescription is not guaranteed, and compounded drugs are not FDA-approved.
FAQ
No. Semaglutide is a prescription-only medication. Avoid websites that sell it without licensed clinician screening, because this is a major safety red flag.
There is no single semaglutide price. Cost depends on the product, pharmacy, insurance coverage, prior authorization, cash-pay option, and care model. At Chia, compounded semaglutide injection plans currently start at $249/mo.
Sometimes. Insurance coverage depends on the product, diagnosis, plan rules, prior authorization, deductible, and pharmacy benefit. Some plans cover semaglutide for type 2 diabetes but not for weight management.
No. Compounded semaglutide is not FDA-approved and is not reviewed by FDA for safety, effectiveness, or quality before marketing. It should be discussed with a licensed clinician and filled through a state-licensed pharmacy.
Treatment length is individualized. Weight regain can occur after stopping semaglutide, so patients should discuss long-term goals, follow-up, side effects, cost, and stopping plans with a clinician.
Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus, but those products have different FDA-approved uses, forms, labeling, and dosing schedules. Compounded semaglutide is a separate regulatory category and is not the same as a brand-name product.
No. Chia’s listed semaglutide offering is compounded semaglutide injection only. Chia does not offer Ozempic, Wegovy, Rybelsus, or oral semaglutide.
References
- 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021.
- 2.Phillips A, Clements JN. Once-Weekly Semaglutide for Weight Management. Journal of Pharmacy Technology. 2022.
- 3.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026.
- 4.Collins L, Costello RA. Semaglutide. StatPearls. 2024.
- 5.Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
- 6.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine. 2023.
- 7.Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
- 8.Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
- 9.Jensterle M, Rizzo M, Haluzík M, Janež A. Efficacy of Semaglutide in Treating Obesity: A Systematic Review. Cureus. 2022.
- 10.Canadian Agency for Drugs and Technologies in Health. Clinical Review - Semaglutide (Wegovy). 2022.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if semaglutide is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
